Answers are grounded in this paper and cite their sources.
Ranolazine and ivabradine offer effective, novel therapeutic options for patients with chronic stable angina who remain symptomatic on or are intolerant to traditional antianginal medications.
Ischaemic heart disease is the common cause of mortality and morbidity in developed countries despite tremendous development in treatment in last two decades. Recently cardiac Ion Channels and other cellular components have become the target of research for new cardiovascular drugs. A number of new drugs have emerged after pre-clinical and clinical trials. Ranolazine by inhibiting late sodium current in ventricular cardiomyocytes and ibavradine by inhibiting If current in pacemaker cells have emerged as effective new antianginal drugs. Both are discussed in this review article. Key Words: Late Sodium current (IPNa), Diastolic tension, After depolarization, If current, heart rate. (University Heart Journal 2007; 3 : 75-78)
No takes yet. Share an insight, caveat, or question.
Das et al. (1970) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: